Amneal (NYSE: AMRX) EVP Andrew Boyer granted time- and performance-based RSUs

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

BOYER ANDREW S reported acquisition or exercise transactions in this Form 4 filing.

Amneal Pharmaceuticals Executive Vice President Andrew S. Boyer reported awards of 65,359 restricted stock units and 65,359 performance-based restricted stock units. Each unit represents a contingent right to receive one share of Class A common stock if vesting conditions are met.

The time-based restricted stock units vest in four equal annual installments beginning on March 2, 2027. The performance-based units are tied to average closing price targets over a three-year period ending February 28, 2029, with payout ranging from 0% to 200% of a 65,359-share target and a maximum of 65,359 shares issuable under the award.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider BOYER ANDREW S

Role Executive Vice President

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	65,359	$0.00	--
Grant/Award	Performance-Based Restricted Stock Units	65,359	$0.00	--

Holdings After Transaction: Restricted Stock Units — 65,359 shares (Direct); Performance-Based Restricted Stock Units — 65,359 shares (Direct)

Footnotes (1)

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. The restricted stock units vest in four equal annual installments beginning on March 2, 2027. Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Represents a performance-based restricted stock unit grant of 65,359 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.

Form 4 Insider Transactions: What Each Field Means →

03/03/2026 - 04:26 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BOYER ANDREW S

(Last)

(First)

(Middle)

C/O AMNEAL PHARMACEUTICALS, INC.

(Street)

BRIDGEWATER

08807

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Amneal Pharmaceuticals, Inc. [ AMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Executive Vice President

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	03/02/2026		A		65,359		⁽²⁾	⁽²⁾	Class A Common Stock	65,359	$0	65,359	D
Performance-Based Restricted Stock Units	⁽³⁾	03/02/2026		A		65,359		⁽⁴⁾	⁽⁴⁾	Class A Common Stock	65,359	$0	65,359	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

2. The restricted stock units vest in four equal annual installments beginning on March 2, 2027.

3. Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

4. Represents a performance-based restricted stock unit grant of 65,359 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period.

Remarks:

	/s/ Denis Butkovic, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Amneal Pharmaceuticals (AMRX) executive Andrew S. Boyer report on this Form 4?

Andrew S. Boyer reported receiving 65,359 restricted stock units and 65,359 performance-based restricted stock units. Each unit represents a contingent right to one share of Amneal Class A common stock, subject to time-based vesting and, for performance units, stock price performance targets.

How do the restricted stock units for AMRX executive Andrew S. Boyer vest?

The restricted stock units vest in four equal annual installments starting March 2, 2027. This means one-quarter of the 65,359 units is scheduled to vest each year over four years, assuming continued service and satisfaction of any applicable conditions.

What are the performance conditions on Andrew S. Boyer’s AMRX performance-based RSUs?

The 65,359 performance-based RSUs vest based on Amneal Class A common stock achieving specified average closing price targets over a three-year performance period. Depending on results, payout can range from 0% to 200% of the 65,359-share target at the end of the period.

When do Andrew S. Boyer’s performance-based RSUs in Amneal (AMRX) vest?

Any earned performance-based restricted stock units vest in full on February 28, 2029. This date marks the end of the three-year performance period used to assess whether Amneal’s Class A common stock achieved the required average closing price targets.

What is the maximum number of AMRX shares issuable under Andrew S. Boyer’s performance-based award?

The filing states the number of performance-based restricted stock units reported represents the maximum shares issuable. For this award, that maximum is 65,359 shares of Amneal’s Class A common stock, subject to satisfaction of the stock price performance conditions.

Does Andrew S. Boyer pay a purchase price for the AMRX restricted stock units granted?

The reported transaction price per share for both the restricted stock units and performance-based restricted stock units is $0.00. This indicates the awards were granted as equity compensation rather than purchased on the open market at a cash price per share.